Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are Zenas BioPharma Insiders Buying or Selling?
Zenas BioPharma (ZBIO) has had no reported insider transactions in the past 90 days. The most recent was MOULDER LEON O JR, who bought 60,000 shares at $16.88 on May 18, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the ZBIO AI Score. For government officials trading this stock, see ZBIO congressional trading.
Who’s Trading Zenas BioPharma Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Harwin Peter Evan | Bought $9M | 2 | Mar 31, 2026 |
| MOULDER LEON O JR | Bought $7.6M | 15 | May 18, 2026 |
| Hongbo Lu | Bought $7.2M | 4 | Mar 31, 2026 |
| Simeon George | Bought $2.4M | 2 | Oct 9, 2025 |
| PATRICK ENRIGHT | Bought $2.3M | 2 | Oct 9, 2025 |
| Nunn Jason Raleigh | Bought $1.2M | 1 | Oct 9, 2025 |
Recent Zenas BioPharma Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| MOULDER LEON O JR | May 18, 2026 | Buy | 60,000 | $16.88 | $1M |
| MOULDER LEON O JR | Apr 29, 2026 | Buy | 35,000 | $17.62 | $620,000 |
| MOULDER LEON O JR | Apr 28, 2026 | Buy | 25,000 | $18.02 | $450,000 |
| Harwin Peter Evan | Mar 31, 2026 | Buy | 150,000 | $20 | $3M |
| MOULDER LEON O JR | Mar 31, 2026 | Buy | 34,000 | $19.31 | $660,000 |
| Hongbo Lu | Mar 31, 2026 | Buy | 75,000 | $20 | $1.5M |
| Hongbo Lu | Mar 31, 2026 | Buy | 3,768 | $18.63 | $70,000 |
| MOULDER LEON O JR | Mar 30, 2026 | Buy | 20,000 | $18.23 | $360,000 |
| Patricia Allen | Feb 13, 2026 | Buy | 4,160 | $26.36 | $110,000 |
| Patricia Allen | Feb 12, 2026 | Buy | 5,700 | $24.34 | $140,000 |
| Patricia Allen | Feb 12, 2026 | Buy | 5,000 | $26.5 | $130,000 |
| Hongbo Lu | Feb 11, 2026 | Buy | 25,985 | $22.5 | $580,000 |
| MOULDER LEON O JR | Feb 2, 2026 | Buy | 57,000 | $17.96 | $1M |
| MOULDER LEON O JR | Jan 9, 2026 | Buy | 20,000 | $16.55 | $330,000 |
| MOULDER LEON O JR | Jan 8, 2026 | Buy | 30,000 | $16.3 | $490,000 |
| MOULDER LEON O JR | Jan 7, 2026 | Buy | 50,000 | $16.38 | $820,000 |
| PATRICK ENRIGHT | Oct 9, 2025 | Buy | 105,265 | $19 | $2M |
| Nunn Jason Raleigh | Oct 9, 2025 | Buy | 63,158 | $19 | $1.2M |
| Simeon George | Oct 9, 2025 | Buy | 63,158 | $19 | $1.2M |
| Simeon George | Oct 9, 2025 | Buy | 63,157 | $19 | $1.2M |
| PATRICK ENRIGHT | Oct 9, 2025 | Buy | 11,990 | $20.85 | $250,000 |
| Harwin Peter Evan | Oct 7, 2025 | Buy | 316,219 | $19 | $6M |
| Hongbo Lu | Oct 7, 2025 | Buy | 263,160 | $19 | $5M |
| MOULDER LEON O JR | Oct 7, 2025 | Buy | 36,928 | $20.85 | $770,000 |
| MOULDER LEON O JR | Feb 18, 2025 | Buy | 25,000 | $6.67 | $170,000 |
| Ting Xiao | Feb 7, 2025 | Buy | 10,000 | $7.76 | $78,000 |
| Ting Xiao | Feb 7, 2025 | Buy | 10,000 | $7.76 | $78,000 |
| MOULDER LEON O JR | Dec 4, 2024 | Buy | 45,000 | $9.98 | $450,000 |
| MOULDER LEON O JR | Dec 3, 2024 | Buy | 25,000 | $10.76 | $270,000 |
| MOULDER LEON O JR | Nov 19, 2024 | Buy | 2,500 | $14.57 | $36,000 |
| MOULDER LEON O JR | Nov 18, 2024 | Buy | 7,500 | $15 | $110,000 |
Frequently Asked Questions: Zenas BioPharma Insider Trading
Zenas BioPharma insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Harwin Peter Evan has bought the most ZBIO stock in the last 2 years, with a total value of $9M.
According to our estimates, the total value of insider transactions for Zenas BioPharma in the last 2 years is positive, amounting to $30M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
